C. Kahl et al., PROGNOSTIC-SIGNIFICANCE OF DYSPLASTIC FEATURES OF HEMATOPOIESIS IN PATIENTS WITH DE-NOVO ACUTE MYELOGENOUS LEUKEMIA, Annals of hematology, 75(3), 1997, pp. 91-94
The detection of dysplastic features of hematopoiesis in de novo acute
myeloid leukemia (AML) by light microscopy is defined as AML with tri
lineage myelodysplasia (AML/TLMD). The prognostic relevance of these d
ysplastic features for patients with de novo AML remains unclear. In o
rder to evaluate the role of dysplasia in de novo AML, bone marrow asp
irates from 69 patients were analyzed prospectively and investigated s
eparately for erythropoiesis, granulopoiesis and megakaryopoiesis by t
hree independent investigators. The overall complete remission (CR) ra
te was 48.8% and partial remission (PR) or nonresponders consituted 52
.2% of the patients investigated. The median overall survival time was
5 months with a disease-free interval of 3.5 months for all patients.
Dysgranulopoiesis (DysG) was observed in 30.4%, dysmegakaryopoiesis (
DysM) in 50.7%, and dyserythropoiesis (DysE) in 43.5%. Of all patients
, 26.0% showed trilineage dysplastic features and were thus classified
as AML/TLMD. A significantly worse prognosis (Kaplan-Meyer plot, Stud
ent's t-test) was calculated for those patients with detection of only
DysG (p=0.002), DysM (p=0.02), DysE (p = 0.04) as compared with patie
nts without any dysplastic signs. An unfavorable karyotype was correla
ted with patients showing DysG (P=0.02) and DysM (P=0.04). For these p
atients with an unfavorable karyotype, the occurrence of any dysplasti
c features had no additional prognostic impact. Dysplastic features (D
ysG, DysM, DysE) seem to be an important prognostic factor in de novo
AML correlating with short overall survival. DysG and DysM correlated
well with the appearance of unfavorable chromosomal abnormalities. It
may be reasonable to assume that patients with dysplastic features sho
uld be considered for more aggressive treatment schedules at the time
of diagnosis.